TRAVERE THERAPEUTICS INC's ticker is TVTX and the CUSIP is 89422G107. A total of 156 filers reported holding TRAVERE THERAPEUTICS INC in Q4 2022. The put-call ratio across all filers is 1.15 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $6,351,620 | -76.8% | 710,472 | -60.2% | 0.02% | -78.0% |
| Q2 2023 | $27,432,637 | +239.7% | 1,785,979 | +445.0% | 0.08% | +156.2% |
| Q3 2022 | $8,075,000 | +841.1% | 327,706 | +884.1% | 0.03% | +966.7% |
| Q1 2022 | $858,000 | -97.9% | 33,300 | -97.9% | 0.00% | -98.4% |
| Q1 2021 | $40,155,000 | +137.3% | 1,608,126 | +159.0% | 0.19% | +126.5% |
| Q4 2020 | $16,925,000 | – | 621,000 | – | 0.08% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Finepoint Capital LP | 875,221 | $19,683,720 | 7.52% |
| Deep Track Capital, LP | 6,147,268 | $138,252,057 | 5.68% |
| Kynam Capital Management, LP | 1,563,595 | $35,165,252 | 4.54% |
| GREAT POINT PARTNERS LLC | 1,003,000 | $22,557,470 | 4.43% |
| ARMISTICE CAPITAL, LLC | 7,148,000 | $160,758,520 | 2.32% |
| HighVista Strategies LLC | 121,834 | $2,740,047 | 2.23% |
| MPM BioImpact LLC | 313,642 | $7,053,809 | 1.83% |
| Sofinnova Investments, Inc. | 1,263,721 | $28,421,085 | 1.82% |
| Octagon Capital Advisors LP | 495,000 | $11,132,550 | 1.60% |
| SECTORAL ASSET MANAGEMENT INC | 358,613 | $8,065,206 | 1.55% |